Holy Mountain

Organigram Reports Third Quarter Fiscal 2023 Results

Retrieved on: 
Friday, July 14, 2023
Cannabis, Natural Resources, Purchasing, THCV, Holy Mountain, Drink, Aerosol, Seed, Genetics, Biolab, Ontario Cannabis Retail Corporation, Cannabinoid, Emulsion, Research, WHC, CBG, Public expenditure, PDC, Data, Investment, Power purchase agreement, CBD, Milk, R, THC, Fiscal, Drug, Tea, Fine chemical, Pharmaceutical industry, Phylo (video game), Organizational chart

Q3 Fiscal 2023 saw the introduction of a record-breaking 28 new SKUs to the market for Organigram.

Key Points: 
  • Q3 Fiscal 2023 saw the introduction of a record-breaking 28 new SKUs to the market for Organigram.
  • Organigram has introduced one of its newest high THC cultivars, Tropical Reign, in large format 28g bags, under its Holy Mountain brand.
  • For Fiscal 2023 the Company had approximately $10 million in remaining capex committed to the three facilities.
  • Organigram believes its capital position is healthy and that there is sufficient liquidity available for the near to medium term.

Organigram Reports Second Quarter Fiscal 2023 Results

Retrieved on: 
Wednesday, April 12, 2023
Retail, Specialty, Other Retail, International, International Accounting Standards Board, Holy Mountain, COVID-19, Calendar, Research, Public expenditure, EBITDA, Acquisition, Investment, International Financial Reporting Standards, Webcast, Depreciation, Growth, Adjustment, News, Fiscal, Security (finance), Bookkeeping, Organizational chart

Organigram currently expects Q3 Fiscal 2023 net revenue to be higher than that of Fiscal Q3 2022 and Fiscal Q2 2023.

Key Points: 
  • Organigram currently expects Q3 Fiscal 2023 net revenue to be higher than that of Fiscal Q3 2022 and Fiscal Q2 2023.
  • In addition, the anticipated continuation of international shipments is expected to generate higher net revenue in Q3 Fiscal 2023 as compared to Q3 Fiscal 2022.
  • The Company expects to maintain positive Adjusted EBITDA throughout Fiscal 2023.
  • The Company forecasts a cash capex spend of approximately $32 million for Fiscal 2023 and if completed as planned during Fiscal 2023, the Company expects to generate positive free cash flows ("FCF") by the end of calendar 2023.

Organigram Revolutionizes Hash with SHRED X Rip-Strip Hash

Retrieved on: 
Monday, February 27, 2023
Cannabis, Retail, Other Retail, Specialty, Natural Resources, Food, Beverage, TSX, Hash, Stock, Senior, OGI, Marketing, R, THC, Innovation, Organizational chart, History, GO, Multimedia, Cryptocurrency, Holy Mountain, Tremblant, Joint

View the full release here: https://www.businesswire.com/news/home/20230227005324/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230227005324/en/
    SHRED-X Rip Strip Hash (Graphic: Business Wire)
    SHRED X Rip-Strip Hash is an extension of the Company’s highly popular SHRED product portfolio, which includes SHRED pre-milled flower, SHRED Jar of Joints, SHRED’ems gummies and SHRED X Vapes.
  • SHRED X Rip-Strip Hash makes it easy to roll your own hash-infused pre-rolls or spice up your bong or pipe bowls with its flavour-forward and convenient hash Rip Strips.
  • Owing to its super-convenient format, SHRED X Rip-Strip Hash is expected to appeal to:
    A new generation of consumer, who likely has little to no experience consuming hash.
  • SHRED X Rip-Strip Hash seeks to break down this barrier to hash consumption and introduce consumers to an ultra-convenient and intuitive format.

Organigram Reports Record First Quarter Fiscal 2023 Results

Retrieved on: 
Thursday, January 12, 2023
Alternative Medicine, Retail, Health, Other Retail, Other Health, Specialty, News, International Accounting Standards Board, EBITDA, COVID-19, Holy Mountain, International, Adjustment, Calendar, Webcast, Fiscal, Research, Depreciation, Investment, International Financial Reporting Standards, Security (finance), Bookkeeping, Organizational chart

Organigram currently expects Fiscal 2023 revenue to be higher than that of Fiscal 2022.

Key Points: 
  • Organigram currently expects Fiscal 2023 revenue to be higher than that of Fiscal 2022.
  • The Company believes it is better equipped to fulfill demand in Fiscal 2023 with larger harvests expected compared to Fiscal 2022.
  • The Company expects Q2 of Fiscal 2023 revenue to be higher than Q2 of Fiscal 2022.
  • The Company has a $29 million capex budget for Fiscal 2023 and if completed as planned during Fiscal 2023, the Company expects to generate positive free cash flows ("FCF") by the end of calendar 2023.